Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment.

De Smet L, Colin P, Ceelen W, Bracke M, Van Bocxlaer J, Remon JP, Vervaet C.

Pharm Res. 2012 Sep;29(9):2398-406. doi: 10.1007/s11095-012-0765-x. Epub 2012 May 4.

PMID:
22555379
[PubMed - indexed for MEDLINE]
2.

In vivo toxicity and bioavailability of Taxol and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC.

Bouquet W, Ceelen W, Adriaens E, Almeida A, Quinten T, De Vos F, Pattyn P, Peeters M, Remon JP, Vervaet C.

Ann Surg Oncol. 2010 Sep;17(9):2510-7. doi: 10.1245/s10434-010-1028-x. Epub 2010 Mar 26.

PMID:
20339948
[PubMed - indexed for MEDLINE]
3.

Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model.

Bouquet W, Deleye S, Staelens S, De Smet L, Van Damme N, Debergh I, Ceelen WP, De Vos F, Remon JP, Vervaet C.

Pharm Res. 2011 Jul;28(7):1653-60. doi: 10.1007/s11095-011-0401-1. Epub 2011 Mar 18.

PMID:
21424162
[PubMed - indexed for MEDLINE]
4.

In vitro cytotoxicity of paclitaxel/beta-cyclodextrin complexes for HIPEC.

Bouquet W, Boterberg T, Ceelen W, Pattyn P, Peeters M, Bracke M, Remon JP, Vervaet C.

Int J Pharm. 2009 Feb 9;367(1-2):148-54. doi: 10.1016/j.ijpharm.2008.09.035. Epub 2008 Sep 30.

PMID:
18938234
[PubMed - indexed for MEDLINE]
5.

Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.

de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, Pilatou M, Sanidas E, Taflampas P, Kalbakis K, Beijnen JH, Tsiftsis DD.

Ann Surg Oncol. 2008 Apr;15(4):1183-92. doi: 10.1245/s10434-007-9792-y. Epub 2008 Feb 1.

PMID:
18239973
[PubMed - indexed for MEDLINE]
6.

Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.

Muñoz-Casares FC, Rufián S, Arjona-Sánchez Á, Rubio MJ, Díaz R, Casado Á, Naranjo Á, Díaz-Iglesias CJ, Ortega R, Muñoz-Villanueva MC, Muntané J, Aranda E.

Cancer Chemother Pharmacol. 2011 Jul;68(1):267-74. doi: 10.1007/s00280-011-1646-4. Epub 2011 Apr 17.

PMID:
21499894
[PubMed - indexed for MEDLINE]
7.

Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.

Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH, Kim SJ.

J Surg Oncol. 2010 Feb 1;101(2):149-55. doi: 10.1002/jso.21448.

PMID:
20035540
[PubMed - indexed for MEDLINE]
8.

Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.

Lu H, Li B, Kang Y, Jiang W, Huang Q, Chen Q, Li L, Xu C.

Cancer Chemother Pharmacol. 2007 Feb;59(2):175-81. Epub 2006 May 23.

PMID:
16718469
[PubMed - indexed for MEDLINE]
9.

In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.

Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, Seo MH.

J Control Release. 2001 May 14;72(1-3):191-202.

PMID:
11389998
[PubMed - indexed for MEDLINE]
10.

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.

Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M.

J Clin Oncol. 1995 Dec;13(12):2961-7.

PMID:
8523061
[PubMed - indexed for MEDLINE]
11.

The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer.

Muñoz-Casares FC, Rufián S, Rubio MJ, Díaz CJ, Díaz R, Casado A, Arjona A, Muñoz-Villanueva MC, Muntané J.

Clin Transl Oncol. 2009 Nov;11(11):753-9.

PMID:
19917539
[PubMed - indexed for MEDLINE]
12.

[Preparation, characterization of paclitaxel-loaded Pluronic P105 polymeric micelles and in vitro reversal of multidrug resistant tumor].

Wang YZ, Fang XL, Li YJ, Zhang ZW, Han LM, Sha XY.

Yao Xue Xue Bao. 2008 Jun;43(6):640-6. Chinese.

PMID:
18822969
[PubMed - indexed for MEDLINE]
13.

Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.

Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T.

BMC Cancer. 2006 Jun 22;6:162.

PMID:
16792796
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

[The inhibitory effect of paclitaxel nanoparticles on ovarian cancer xenografts and lymphatic targeting].

Lu HX, Xu CJ, Li B, Kang Y, Huang Q, Li LM, Chen QH.

Beijing Da Xue Xue Bao. 2006 Oct 18;38(5):483-6. Chinese.

PMID:
17068619
[PubMed - indexed for MEDLINE]
Free Article
15.

Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation.

Ganta S, Devalapally H, Amiji M.

J Pharm Sci. 2010 Nov;99(11):4630-41. doi: 10.1002/jps.22157.

PMID:
20845461
[PubMed - indexed for MEDLINE]
16.

Phospholipid-Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel.

Liang H, Yang Q, Deng L, Lu J, Chen J.

Drug Dev Ind Pharm. 2011 May;37(5):597-605. doi: 10.3109/03639045.2010.533276.

PMID:
21469948
[PubMed - indexed for MEDLINE]
17.

Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105 polymeric micelles.

Wang Y, Li Y, Zhang L, Fang X.

Arch Pharm Res. 2008 Apr;31(4):530-8. doi: 10.1007/s12272-001-1189-2. Epub 2008 May 1.

PMID:
18449513
[PubMed - indexed for MEDLINE]
18.

Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.

Vassileva V, Grant J, De Souza R, Allen C, Piquette-Miller M.

Cancer Chemother Pharmacol. 2007 Nov;60(6):907-14. Epub 2007 Mar 21.

PMID:
17375303
[PubMed - indexed for MEDLINE]
19.

Intraperitoneal treatment using taxol is effective for experimental peritoneal carcinomatosis in a rat model.

Hribaschek A, Ridwelski K, Pross M, Meyer F, Kuhn R, Halangk W, Boltze C, Lippert H.

Oncol Rep. 2003 Nov-Dec;10(6):1793-8.

PMID:
14534698
[PubMed - indexed for MEDLINE]
20.

Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.

Park JH, Park JH, Hur HJ, Woo JS, Lee HJ.

Eur J Pharm Sci. 2012 Feb 14;45(3):296-301. doi: 10.1016/j.ejps.2011.11.021. Epub 2011 Dec 8.

PMID:
22172604
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk